HEMODILUTION AND CEREBRAL ISCHEMIA

该项目的目的是研究中风的治疗， 使用基础研究技术进行血液稀释。 目前，使用 低分子量右旋糖酐（LMWD）血液稀释 正在临床试验中进行评估。 血液稀释和 在急性卒中中，将使用 局灶性脑缺血动物模型及双标记 放射自显影技术测定局部脑血 脑血流（LCBF）和局部脑pH（LCpH） 科. 数据分析将侧重于LCBF的测量， LCpH及其在解剖区域的比值。 的边界区域 缺血区域将被评价为血液稀释的区域 会影响中风的预后 血液稀释和 血液浓缩将用于慢性中风模型， 使用神经病理学和放射自显影进行评价 的搜索. 将对动物进行各种血细胞比容研究， 最佳红细胞压积水平 血浆和LMWD均将 用作血液稀释剂，以揭示任何特定的有益效果 由于其作为抑制剂的特性， 红细胞和血小板的聚集。

The aim of this project is to study the treatment of stroke with hemodilution using basic research techniques. Currently the use of hemodilution with low molecular weight dextran (LMWD) is being evaluated in clinical trials. Hemodilution and hemoconcentration will be evaluated in acute stroke using an animal model of focal cerebral ischemia and the double label autoradiographic technique for determining local cerebral blood flow (LCBF) and local cerebral pH (LCpH) in the same brain section. Data analysis will focus on the measurement of LCBF, LCpH and their ratio in anatomical regions. The border zone of the ischemic area will be evaluated as an area where hemodilution could effect stroke outcome. Hemodilution and hemoconcentration will be used in a chronic model of stroke and evaluated using both neuropathological and autoradiographic criteria. Animals will be studied at various hematocrits to find the optimal hematocrit level. Both plasma and LMWD will be used as hemodilutants to uncover any specific, beneficial effect of LMWD on stroke outcome due to its properties as an inhibitor of red cell and platelet aggregation.